Abstract
Accurate identification of seizure activity, both clinical and subclinical, has important implications in the management of epilepsy. Accurate recognition of seizure activity is essential for diagnostic, management and forecasting purposes, but patient-reported seizures have been shown to be unreliable. Earlier work has revealed accurate capture of electrographic seizures and forecasting is possible with an implantable intracranial device, but less invasive electroencephalography (EEG) recording systems would be optimal. Here, we present preliminary results of seizure detection and forecasting with a minimally invasive sub-scalp device that continuously records EEG.
Five participants with refractory epilepsy who experience at least two clinically identifiable seizures monthly have been implanted with sub-scalp devices (Minder™), providing two channels of data from both hemispheres of the brain. Data is continuously captured via a behind-the-ear system, which also powers the device, and transferred wirelessly to a mobile phone, from where it is accessible remotely via cloud storage. EEG recordings from the sub-scalp device were compared to data recorded from a conventional system during a 1-week ambulatory video-EEG monitoring session. Suspect epileptiform activity (EA) was detected using machine learning algorithms and reviewed by trained neurophysiologists. Seizure forecasting was demonstrated retrospectively by utilising cycles in EA and previous seizure times.
The procedures and devices were well tolerated, and no significant complications have been reported. Seizures were accurately identified on the sub-scalp system, as confirmed by periods of concurrent conventional scalp EEG recordings. The data acquired also allowed seizure forecasting to be successfully undertaken. The area under the receiver operating characteristic curve (AUC score) achieved (0.88) is comparable to the best score in recent, state-of-the-art forecasting work using intracranial EEG.
Competing Interest Statement
PJK, ESN, MIM, DRF and MJC have a financial interest in Seer Medical Pty. Ltd. MJC, SGR, JH, TLC and RJH have a financial interest in Epi-Minder Pty. Ltd. MPR has a research collaboration with UNEEG medical and has been a member of their advisory board. MPR is supported by the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, and by the Medical Research Centre for Neurodevelopmental Disorders (MR/N026063/1). BHB has a financial interest in Cadence Neurosciences Inc., and has received non financial research support (devices for a study) from Medtronic Inc.
Clinical Trial
ACTRN 12619001587190
Funding Statement
This project was supported by the 'My Seizure Gauge' grant from the Epilepsy Foundation of America.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
St Vincent's Hospital Melbourne Human Research Ethics Committee (HREC 063/15)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Minor text revisions to clarify methods
Data Availability
Data was collected as part of an ongoing clinical trial. Following completion of the trial, data can be made available upon reasonable request to the corresponding author (MJC).
